ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DNLI vs BEAM // EV/EBITDA & P/E VALUATION

Denali Therapeutics Inc. (NASDAQ) VS. Beam Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DNLI 2 — BEAM 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNLI VS. BEAM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DNLI BEAM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.10% -2.90 BEAM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -13.67% -12.09% -1.58 BEAM /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -57.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 120.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.87 6.00 +4.87 DNLI /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 BEAM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 57.7 -12.41 BEAM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.09B $2.98B $109.4M DNLI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DNLI REV BEAM REV DNLI GROSS % BEAM GROSS % DNLI FCF BEAM FCF
FY 2025 $0 $139.7M — — -$422.1M -$360.0M
FY 2024 $0 $63.5M — — -$363.6M -$356.2M
FY 2023 $330.5M $377.7M — — -$358.0M -$149.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNLI // BETA —
BEAM // BETA —